Human Services hearing on House Bill 1321 centers on lowering medical cannabis costs, extending card renewals and increasing possession limits

The Human Services Committee opened a hearing on House Bill 1321, which sponsor Representative Steve Vetter (R–District 18, Grand Forks) said is intended "to lower costs for patients and the dispensaries while allowing more pain relief for clients or for patients." Representative Vetter told the committee the bill would lower dispensary fees by 10 percent, require medical cardholders to renew every two years instead of annually, and increase the amount a patient may purchase to take advantage of lower per-unit pricing.

Why it matters: proponents said the package would reduce out-of-pocket costs for patients and help dispensaries remain viable as neighboring states expand recreational markets. Opponents raised public-safety concerns tied to larger on-hand possession amounts.

Vetter told the committee the renewal change would cut patient expenses tied to annual medical visits. He described the per-visit costs and application expenses: "Between paying for your card and paying for the nurse doctor appointment, it's right around about $200." He said the card fee itself is small ("I think the actual fee is $25. It's either 25 or 50, but I think it's 25") and suggested fee-timing changes could mitigate a fiscal note attached to the bill.

Supporters at the hearing included Burleigh County Commissioner Steve Bakken, who said increased allotments and longer renewal periods would aid low-income patients and reduce burdens created by applying each year in the state's BioTrac system. Bakken warned that neighboring states' legalization had already reduced sales in parts of North Dakota and said preserving the medical program was important to keep patients in the regulated system.

The only recorded organized opposition came from Kelvin Benson, speaking for the North Dakota Peace Officers Association. Benson said, "The North Dakota Peace Officers Association does not support, house bill 1321." He told the committee the association's primary concern was the total amount a patient could possess at one time under the revised language and requested the bill be given a do-not-pass recommendation. He referenced language in the bill's possession section (noting committee discussion of a referenced section "2 b" or "21 b") as the focal point of the association's concerns.

Discussion in the hearing ranged from patient cost relief and dosing consistency to enforcement worries tied to larger possession allowances. Committee members asked clarifying questions about prescription timing and possession limits; testimony described the patient's supply as typically written for about 30 days.

The committee closed the hearing on House Bill 1321 with no committee vote recorded and immediately opened the hearing on House Bill 1203.